Clinical Trial Update: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL [Phase 2]

View source ↗

Summary

A phase 2 clinical trial is evaluating the feasibility and clinical efficacy of atezolizumab as consolidation therapy in high-risk diffuse large B-cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: NHL, DLBCL | Phase 2 | Status: ACTIVE_NOT_RECRUITING